Search

Objective To assess the efficacy of docetaxel rechallenge on castration-resistant prostate cancer (mCRPC) patients and to analyze prognostic factors. Methods We retrospectively reviewed the medical history of 120 mCRPC patients treated with the first-line docetaxel chemotherapy effectively and progressed with docetaxel rechallenge. Coprimary end points were prostate specific antigen progression-free survival (PSA PFS) after the first sequence docetaxel chemotherapy, prostate specific antigen progression-free survival after docetaxel rechallenge (Rechallenge PSA PFS) and overall survival (OS). Univariable and multivariable Cox analyses were performed to determine prognostic factors associated with PSA PFS, Rechallenge PSA PFS and OS. Results At a median follow-up of 32.73 months, 30(25%) patients were still alive. The median PSA PFS, Rechallenge PSA PFS and OS were 13.89(7.67-39.00), 5.29(1.25-20.00) and 27.13(12.40-60.50) months, respectively. In multivariate analysis, treatment-free interval between the first sequence docetaxel chemotherapy and docetaxel rechallenge (> 6 months vs. ≤6 months) was independent predictor for PSA PFS. Response of docetaxel rechallenge (partial vs. no partial) was independent predictor for Rechallenge PSA PFS. mCRPC baseline serum-PSA and response of docetaxel rechallenge (partial vs. no partial) were independent predictors for OS. Conclusion These results further support the favorable profile of docetaxel rechallenge in mCRPC patients who were effectively treated with first-line docetaxel.

Objective To assess the efficacy of docetaxel plus ADT on mHSPC patients and analyze the prognostic factors. Methods We retrospectively reviewed the clinical data of 107 mHSPC patients treated with docetaxel plus ADT. Co-primary end points were PSA PFS and rPFS. Univariable and multivariable Cox analyses were performed to determine prognostic factors for PSA PFS and rPFS. Results The median follow-up time was 36 months, and 13 (12.1%) patients died. The median PSA PFS and rPFS were 34.000 (30.878-37.122) and 33.000 (30.031-35.969) months, respectively. Univariate analysis results showed that the serum PSA, PSA nadir at 7th month (≤0.2ng/dl vs. > 0.2ng/dl), number of chemotherapy cycles (≤6 vs. 7-12), ECOG PS (0-1 vs. 2) and visceral disease (yes vs. no) were independent predictors for PSA PFS and rPFS. Multivariate analysis results showed that PSA nadir at 7th month (≤0.2ng/dl vs. > 0.2ng/dl) and visceral disease (yes vs. no) were independent predictors for PSA PFS and rPFS. Conclusion The effect of docetaxel plus ADT on patients with mHSPC in China is favorable. PSA nadir at 7th month (≤0.2ng/dl vs. > 0.2ng/dl) and visceral disease (yes vs. no) are independent predictors for PSA PFS and rPFS.

Background: Large skeletal defects due to postosteomyelitis are uncommon, and they present a challenging reconstructive problem. The aim of our study was to summarize our experience performing a distraction osteogenesis technique using an intramedullary nail and a monolateral external fixator in the reconstruction of massive postosteomyelitis skeletal defects of the femur. Methods: Between January 1998 and October 2004, 17 patients with massive postosteomyelitis skeletal defects of the femur (11 men and 6 women), underwent the reconstruction procedure. After osteotomy of diaphysis of the femur, we inserted an intramedullary nail into the femur, and we placed a monolateral external fixator with half-pins lateral to the nail. Lengthening was started on the seventh postoperative day at a rate of 1 mm/d. Once we achieved solid bone union, we removed the monolateral external fixator; the intramedullary nail remained for bone consolidation until reconstruction was complete. We assessed the outcomes clinically and radiographically at a mean of 70.3 months postoperatively. Results: At follow-up (mean 70.3, range 14.0-96.0 mo), all the skeletal defects were filled, bone union at docking sites was achieved without bone graft and leg length discrepancies were less than 2.5 cm in all patients. The mean gain in length was 12.9 (range 10.2-18.4) cm. According to Paley and Maar's evaluation criteria, we graded the bone results as excellent for 10 patients, good for 5, fair for 1 and poor for 1. We graded the functional results as excellent for 12 patients, good for 4 and fair for 1. The mean external fixator index was 18.1 d/cm; the consolidation index was 35.7 d/cm. Ten patients experienced pin infection, and 1 patient experienced a recurrence of deep infection. There were no neurologic or vascular injuries. Conclusion: Our study demonstrates that a distraction osteogenesis technique using an intramedullary nail and a monolateral external fixator is a reliable method for the reconstruction of massive postosteomyelitis skeletal defects. Contexte : Les lacunes osseuses majeures consecutives a une osteomyelite sont rares et causent des problemes de reconstruction difficiles. Notre etude visait a resumer notre experience d'une technique d'osteogenese par distraction utilisant un clou intramedullaire et un fixateur externe monolateral pour reconstruire des lacunes osseuses massives du femur consecutives a une osteomyelite. Methodes : Entre janvier 1998 et octobre 2004, 17 patients ayant des lacunes osseuses massives du femur consecutives a une osteomyelite (11 hommes et 6 femmes) ont subi une intervention de reconstruction. Apres une osteotomie de la diaphyse du femur, nous avons introduit un clou intramedullaire dans le femur et mis en place un fixateur externe monolateral avec des demi-broches posees lateralement au clou. On a commence l'allongement le septieme jour apres l'intervention a raison de 1 mm/j. Apres la fusion solide de l'os, nous avons enleve le fixateur externe monolateral. Le clou intramedullaire est demeure en place pour la consolidation de l'os jusqu'a ce que la reconstruction soit terminee. Nous avons evalue les resultats par des examens cliniques et radiographiques 70,3 mois en moyenne apres l'intervention. Resultats : Au suivi (moyenne de 70,3, intervalle de 14,0 a 96,0 mois), toutes les lacunes osseuses etaient comblees, la fusion de l'os au site d'amarrage s'etait produite sans greffe osseuse et la difference au niveau de la longueur des jambes etait inferieure a 2,5 cm chez tous les patients. L'allongement moyen s'est etabli a 12,9 (intervalle de 10,2 a 18,4) cm. Selon les criteres d'evaluation de Paley et Maar, nous avons juge les resultats osseux excellents chez 10 patients, bons chez 5, moyens chez 1 et mediocres chez 1 autre. Nous avons juge les resultats fonctionnels excellents chez 12 patients, bons chez 4 et moyens chez 1. L'indice moyen du fixateur externe etait de 18,1 j/cm, l'indice de consolidation s'est etabli a 35,7 j/cm. Dix patients ont eu une infection aux broches et un patient a ete atteint d'une infection profonde repetitive. Il n'y a pas eu de traumatisme neurologique ou vasculaire. Conclusion : Notre etude demontre qu'une technique d'osteogenese par distraction utilisant un clou intramedulaire et un fixateur externe monolateral constitue une methode fiable de reconstruction de lacunes osseuses massives consecutives a une osteomyelite., Hematogeneous osteomyelitis is rarely seen in the femur; however, it may lead to poor outcomes owing to delayed or inappropriate treatments, especially in developing countries. Some severe chronic osteomyelitis may [...]

The present study tested whether myrtol improves post-traumatic knee osteoarthritis (PTKO) by regulating the reactive oxygen species (ROS), transforming growth factor β1 (TGF-β1) and apoptosis in a mouse model. PTKO model mice were administered with 150, 300 or 450 mg/kg myrtol for 8 weeks. ELISA analysis was used to measure tumor necrosis factor-α, interleukin-6, malondialdehyde, superoxide dismutase, reactive oxygen species and TGF-β1 levels. Caspase-3 and Bax protein expressions were analyzed using western blot analysis. In the current study, treatment with myrtol improved the tissue damage and osteoarthritis score, while it also reversed the subchondral bone thickness, subchondral bone density, trabecular bone volume/relative trabecular bone volume ratio and trabecular bone spacing in PTKO mice. The activity of tumor necrosis factor α, interleukin-6, TGF-β1, malondialdehyde, superoxide dismutase and ROS were effectively inhibited, and the protein expression of caspase-3 and Bax were clearly suppressed by treatment with myrtol in a mouse model of PTKO. In conclusion, the results demonstrated that myrtol treatment improved PTKO through the suppression of inflammation, oxidative stress, ROS, TGF-β1 and Bax/caspase-3 in mice, and myrtol may be a potential agent for clinical therapy. [ABSTRACT FROM AUTHOR]

In this work, a batch of novel ternary hybrids (SiC@C-Fe3O4), characterized by SiC nanowires core, carbon shell, and adhered Fe3O4 nanoparticles were controllably synthesized via surface carbonization of SiCnw followed by hydrothermal reaction. Carbon, which was derived from SiC with nanometer thickness, possesses an amorphous structure, while Fe3O4 nanoparticles are in a crystalline state. Simultaneously, the inducement of Fe3O4 nanoparticles can provide significant magnetic loss, which is well-tuned by changing the molar content of iron precursors (FeCl3·6H2O and FeCl2·4H2O). SiC@C-Fe3O4 hybrids show great electromagnetic absorption performance owing to the synergy effect of dielectric and magnetic losses. The minimum refection loss can reach to −63.71 dB at 11.20 GHz with a thickness of 3.10 mm, while the broad effective absorption bandwidth (EAB) can reach to 7.48 GHz in range of 10.52–18.00 GHz with a thickness of 2.63 mm. Moreover, the EAB can also cover the whole X band and Ku band. The outstanding performance of the obtained material implys that it is a promising candidate as an electromagnetic absorber. [ABSTRACT FROM AUTHOR]

Objective: To study the inhibitory effect of CD133 monoclonal antibody labeled with ¹³¹I (¹³¹I-CD133mAb) on Huh-7 human liver cancer cell line overexpressing CD133 antigen in vitro and in mouse models bearing the tumor cell xenograft., Methods: ¹³¹I-CD133mAb was prepared by chloramines-T method and evaluated for its stability. Flow cytometry and immunohistochemistry were used to detect the expression of CD133 in Huh-7 cells and in Huh-7 cell-derived tumors, respectively. Huh-7 cells treated with ¹³¹I-CD133mAb plus cisplatin (DDP), ¹³¹I -CD133mAb, DDP, or no treatment (blank control) were examined for cell proliferation suppression by MTT assay with the IC₅₀ calculated. BALB/c mice bearing subcutaneous Huh-7 cell xenograft in the right forelegs were treated with ¹³¹I -CD133mAb, DDP, or both every two days for two weeks. The tumor size and volume were measured twice a week, and pathological examination of the tumor was carried out after the treatments. The tumor inhibition rate was calculated and tumor cell apoptosis observed with HE staining., Results: The labeling ratio of ¹³¹I-CD133mAb was 90.25% and the radiochemical purity was 97.78%. Huh-7 cells showed obviously higher CD133 expression than HepG2 cells. ¹³¹I-CD133mAb combined with DDP group resulted in a significantly higher tumor inhibition rate than other treatments in the tumor-bearing mice., Conclusion: ¹³¹I-CD133mAb can inhibit the growth of liver cancer cells with a high CD133 expression both in vivo and in vitro.

Objective: To investigate the effect of amphotericinB (AmB) on migration and invasion of esophageal carcinoma Eca109 cells exposed to hypoxia and explore the molecular mechanisms., Methods: Routinely cultured esophageal carcinoma Eca109 cells were treated with 0, 1.25, 2.5, or 5 µg/ml AmB in hypoxic condition (3% O2, 5% CO2, and 92% N2) for 24 h. The cell migration and invasion were assessed by cell scratch test and Transwell chamber assay, respectively. Real-time quantitative PCR and Western blotting were used to detect the mRNA and protein expressions of hypoxia-inducible factor-1α (HIF-1α), matrix metalloproteinase-2 (MMP-2), and E-cadherin in the cells, respectively., Results: Compared with the control cells, the cells treated with different doses of AmB showed attenuated ability of migration and invasion (P<0.05). AmB treatment resulted in significantly lowered mRNA and protein expressions of MMP-2 (P<0.05) and increased expressions of E-cadherin (P<0.05); the protein expression of HIF-1α decreased significantly in cells after AmB treatment (P<0.05) but its mRNA levels showed no significant changes (P>0.05)., Conclusion: AmB can suppress the migration and invasion of esophageal carcinoma Eca109 cells in hypoxic microenvironment possibly by regulating the expressions of HIF-1α, MMP-2 and E-cadherin.